Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
PURPOSE AND OBJECTIVES:
Primary Objective To evaluate the activity of Sorafenib plus protracted, daily temozolomide
in patients with recurrent glioblastoma multiforme (GBM) as measured by 6-month PFS.
Secondary Objectives To evaluate the safety and toxicity of combination therapy using
Sorafenib plus temozolomide; To determine the pharmacokinetics of Sorafenib when combined
with temozolomide in patients on and not on concurrent EIAC medications.